Antibiotic-free treatment of dairy cows underway

October 11, 2018, CORDIS
Antibiotic-free treatment of dairy cows underway
Credit: Wiratchai wansamngam, Shutterstock

Is antibiotic resistance signalling the end for modern treatments of udder infections in the dairy industry? Not so fast, according to researchers who are developing breakthrough technology that's effective against all tested bacteria.

Antibiotic resistance is increasing dramatically all over the world. As more and more become resistant to the antibiotics designed to kill them, they render these drugs ineffective, undermining our ability to treat . Unless urgent action is taken, the World Health Organization foresees us entering a post-antibiotic era where common infections and minor injuries can once again prove fatal.

The EU-funded project PanaMast is tackling the problem of by focusing on , a commonly occurring inflammation of the udder affecting dairy cattle worldwide. While mastitis is normally treated using conventional antibiotics, PanaMast is developing the world's first non-antibiotic solution to treat lactating cows.

Health and economic benefits of the innovative technology

Called long-acting reactive species (LARS), the novel non-antibiotic antimicrobial technology has so far been found to be effective against all tested microorganisms, including antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). More importantly, it doesn't induce resistance. Highly effective against both gram-negative and gram-positive bacteria, LARS has also demonstrated an excellent safety/low toxicity profile in vivo and in vitro. It can be administered in different ways, including in aerosolised or nebulised form, and its low minimum inhibitory concentrations make it appropriate for a wide range of therapeutic applications.

Besides the health advantages it presents, the new treatment also offers significant economic benefits to dairy farmers. With , farmers lose milk revenues, since milk from cows undergoing treatment cannot be sold for a period of time during and after treatment. Furthermore, when the don't work, infected cows have to be culled. This costs the European and American dairy industries over EUR 3 billion a year. But when infected cows are treated with LARS, milk can potentially be sold both during and after treatment, significantly benefiting farmers and milk producers.

In a press release published by project leader Westway Health, CEO Dr. Ruairi Friel explained the company's innovative approach: "The genesis of the idea was knowing that there are other ways to kill bacteria like MRSA. This is done every day around the world using disinfectants for example, or through steam cleaning. What we have been able to develop is a new method of killing bacteria which does not harm living tissue. Our solution is based on a combination of compounds inspired by nature, and if we can develop and scale our solution we believe we can help tackle this global challenge of antibiotic-resistance."

By the end of the 24-month project, PanaMast (Progressing a non-antibiotic antimicrobial treatment for Bovine Mastitis towards market – PanaMast) intends to have completed the testing of its novel product and have it ready for market implementation (technology readiness level 8). Subject to regulatory approval by the European Medicines Agency, the aim is to have the product available on the market by 2021 or 2022.

Explore further: Rapid diagnostic test for bovine mastitis on the horizon

More information: PanaMast project web page: westwayhealth.com/h2020/

Related Stories

Rapid diagnostic test for bovine mastitis on the horizon

May 16, 2018

Abingdon Health, a tenant at the University of Birmingham's bio-incubator, is developing a rapid diagnostic test for bovine mastitis, a common and serious health problem in dairy cows, which has an estimated £14-23 billion ...

Novel antibiotic resistance gene in milk

April 27, 2017

Researchers of the University of Bern have identified a new antibiotic resistance gene in bacteria from dairy cows. This gene confers resistance to all beta-lactam antibiotics including the last generation of cephalosporins ...

Recommended for you

Strep bacteria compete for 'ownership' of human tissue

December 10, 2018

A well-accepted principle in the animal kingdom—from wasps to deer—is that creatures already occupying a habitat nearly always prevail over competitors from the same species that arrive later. Such infighting for the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.